Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed and dated written informed consent~* Male or females ≥ 40 years of age~* Established clinical history of COPD by ATS/ERS definition~* Females are eligible to enter and participate if of non-childbearing potential, or if of child bearing potential, has a negative serum pregnancy test at screening, and agrees to one of the acceptable contraceptive methods listed in protocol, used consistently and correctly~* Former or current smoker \> 10 pack years~* Post-albuterol spirometry criteria: FEV1/FVC ratio ≤ 0.70 and FEV1 ≤ 70% of predicted normal (NHANES III)~Exclusion Criteria:~* Current diagnosis of asthma~* Subjects with other respiratory disorders including active tuberculosis, α1-antitrypsin deficiency, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases~* Lung volume reduction surgery within previous 12 months~* Clinically significant abnormalities not due to COPD by chest x-ray~* Hospitalized for poorly controlled COPD within 12 weeks of Screening~* Poorly controlled COPD 6 weeks prior to Screening, defined as acute worsening of COPD that is managed by the subject with corticosteroids or antibiotics or that requires treatment prescribed by a physician~* Lower respiratory infection requiring antibiotics 6 weeks prior to Screening~* Uncontrolled or clinically significant (in opinion of PI) cardiovascular, hypertension, neurological, psychiatric, renal, hepatic, immunological, endocrine, peptic ulcer disease, or hematological abnormalities~* Carcinoma not in complete remission for at least 5 years~* Subjects with history of hypersensitivity to study medications (e.g., beta-agonists, corticosteroid) or components of inhalation powder (e.g., lactose, magnesium stearate)~* Subjects with history of severe milk protein allergy that, in opinion of study physician, contraindicates subject's participation~* Known/suspected history of alcohol or drug abuse in the last 2 years~* Women who are pregnant or lactating or plan to become pregnant~* Subjects medically unable to withhold albuterol and/or ipratropium 4 hours prior to spirometry testing at each study visit~* Use of certain medications such as bronchodilators and corticosteroids for the protocol-specific times prior to Visit 1 (the Investigator will discuss the specific medications)~* Long Term Oxygen Therapy (LTOT) or nocturnal oxygen therapy \>12 hours a day~* Participation in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Screening or during the study~* Non-compliance or inability to comply with study procedures or scheduled visits~* Affiliation with investigator site

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fluticasone Furoate / GW642444 (vilanterol) (Type: EXPERIMENTAL): Inhaled Corticosteroid (ICS)/ Long acting Beta Agonist (LABA)
- Fluticasone Propionate / salmeterol (Type: ACTIVE_COMPARATOR): Inhaled Corticosteroid (ICS)/ Long acting Beta Agonist (LABA)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete